Scientific Article

Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial Cancer

Jessica D. Arden, MD, PhD,a,1 Jonathan Dokter, BS, b,1 Muayad F. Almahariq, MD, PhD,a Kimberly Marvin, BS,a Sirisha R. Nandalur, MD,a Zaid Al-Wahab, MD,c Jill Gadzinski, MD,c Barry Rosen, MD,c and Maha Saada Jawad, MDa,*

aDepartment of Radiation Oncology, Beaumont Health System, Royal Oak, Michigan; bOakland University William Beaumont School of Medicine, Rochester, Michigan; cDepartment of Gynecologic Oncology, Beaumont Health System, Royal Oak, Michigan

Received May 20, 2021; accepted August 2, 2021

Abstract

Purpose: This study aimed to evaluate outcomes and toxicity in patients with endometrial cancer per our institutional adjuvant vaginal cuff brachytherapy (VBT) fractionation scheme.

Methods and Materials: We identified women with International Federation of Gynecology and Oncology stages I and II endometrial cancer who underwent surgical staging and adjuvant high-dose-rate VBT without external beam radiation. All patients received 30 Gy in 6 fractions to the upper one-third of the vagina, prescribed to a depth of 5 mm and delivered twice weekly. Toxicities were prospectively elicited at each follow up, and rates of recurrence and survival were retrospectively assessed.

Results: We identified 247 eligible patients treated between 1992 and 2018 with a median follow up of 5.8 years (range, 0.1-24.7 years). Most patients had stage I disease (52% stage IA; 37% stage IB), and 11% of patients were stage II. Deep myometrial invasion was predictive of local recurrence (P = .002). The 5-year rates of local recurrence, regional recurrence, and distant metastases were 5%, 5%, and 7%, respectively. The most common grade 1 toxicities were acute fatigue (11% crude rate), urinary frequency (11%), chronic (>6 months) urinary frequency (13%), urinary incontinence (13%), and vaginal stenosis (21%). There were few grade 2 toxicities (all <5%) and no grade 3 to 5 toxicities.

Conclusions: The adjuvant VBT fractionation scheme of 30 Gy in 6 fractions results in low rates of toxicity, with no grade ≥3 adverse events, and local control rates comparable with those from other published series using different fractionation schemes.

© 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Endometrial cancer is the most common gynecologic malignancy in the United States, with an estimated 65,620 new cases in 2020.1 International Federation of Gynecology and Oncology (FIGO) stages I to II disease constitute two-thirds of new diagnoses, and are treated with a total hysterectomy with bilateral salpingo-oophorectomy,
surgical staging, and lymph node assessment, followed by risk-adapted adjuvant therapy. Patients with high-intermediate risk (HIR) factors (deep myometrial invasion; grade 3 disease; presence of lymphovascular space; and age >50, >60, or >70 depending on other risk factors) receive adjuvant radiation therapy to improve local control. Specifically, adjuvant vaginal brachytherapy (VBT) is preferred because this method provides equivalent local control with improved toxicity compared with external beam radiation therapy (EBRT). For HIR patients, VBT results in a 1.8% rate of vaginal recurrence, but substantially lower rates of gastrointestinal toxicity.

The American Brachytherapy Society (ABS) published guidelines regarding the technical aspects of VBT. In the most recent version of the ABS guidelines, published early 2019, several acceptable dose-fractionation schedules are outlined. Three fractions of 7 Gy prescribed to a depth of 5 mm is commonly used, because this was the fractionation scheme used in the PORTEC-2 study. However, subsequent studies using different dose-fractionation schedules showed similar local control. The ABS guidelines caution that schedules using higher doses per fraction and fewer fractions may result in increased toxicity, although data on the rate of toxicity associated with specific VBT fractionation schemes is lacking.

Before the publication of the ABS guidelines on fractionation choices, we adopted the fractionation scheme of 6 fractions of 5 Gy, prescribed to a depth of 5 mm from the vaginal surface (biologically equivalent dose [BED]10: 45 Gy; equivalent total dose in 2-Gy fractions [EQD2]10: 37.5 Gy). This fractionation was selected with the goal of delivering an adequate radiation dose to reduce local recurrence (LR) while also limiting the dose per fraction to minimize toxicity. We previously published our 2-year recurrence and 4-year survival outcomes, which showed very favorable local control with this fractionation. Herein, we report on acute and chronic toxicity outcomes associated with this fractionation, as well as long-term clinical outcomes.

Methods and Materials

In this retrospective study, we identified all patients with FIGO stages I to II endometrial cancer treated with adjuvant VBT at our institution for whom a minimum of 6 months of follow-up data were available. For the purpose of this study, our goal was to evaluate clinical outcomes and toxicity for patients treated with 30 Gy in 6 fractions. Therefore, only patients who received a dose of 30 Gy delivered in 6 fractions were included. Patients who received adjuvant EBRT or alternative VBT doses were excluded. However, this dose fractionation has been our institutional standard since the early 1990s (before the publication of randomized trials that used other dose fractionation schemes). Therefore, a majority of the patients treated with VBT alone at our institution were treated with this fractionation. Overall, we identified a total of 359 women with early stage endometrial cancer, of whom 247 patients met our criteria of treatment with VBT to 30 Gy in 6 fractions. This study was approved by our institutional review board.

All patients underwent surgical staging with a total abdominal hysterectomy, bilateral salpingo-oophorectomy, with or without pelvic and/or para-aortic lymph node assessment and/or peritoneal cytology. Surgical staging was completed either openly, laparoscopically, or robotically because standards regarding surgical approach changed over time at our institution. The decision to administer chemotherapy was based on individual patient risk factors, such as high-risk histology (eg, clear cell, serous, or carcinosarcoma), tumor grade, and/or lymphovascular space invasion (LVSI).

After surgical staging, all patients received high-dose-rate (HDR) VBT with an Iridium-192 source using a vaginal cylinder. Treatment was initiated after the vaginal cuff healed completely, no sooner than 4 weeks after surgery. All patients received 30 Gy in 6 fractions twice weekly, prescribed to a depth of 5 mm from the vaginal surface. The target included the upper third of the vagina, consisting of a length of 4 cm in 87% of patients. The BED10 for this fractionation is 45 Gy, with EQD210 of 37.5 Gy, both at a depth of 5 mm.

Baseline patient characteristics, treatment details, and follow-up information were retrospectively collected. A typical patient follow-up schedule consisted of visits at 3-month intervals for the initial 2 years, then every 6 months for the next 3 years, alternating between radiation and gynecologic oncologists. Patients followed up annually after 5 years with their gynecologic oncologist, but did not routinely continue to have follow up in the radiation oncology department beyond 5 years. Pelvic examinations (speculum and bimanual) were performed at the time of each follow-up visit, and an assessment of vaginal stenosis was performed at that time. Vaginal length was not routinely recorded. Surveillance imaging was not routinely performed, but ordered at the discretion of the treating physician. Of note, patients were encouraged to use a vaginal dilator after their VBT treatments to help prevent and minimize vaginal stenosis. Specifically, patients were provided with a dilator and asked to use this 3 times per week for a duration of 10 minutes per use, beginning 2 weeks after completion of the VBT and continuing for a minimum of 1 year. Subsequently, patients were encouraged to continue dilator use indefinitely at a frequency of at least once per week.

For the toxicity analysis, rates of genitourinary, gastrointestinal, and gynecologic toxicities were prospectively elicited at each follow-up appointment in the radiation oncology department, and entered into a database beginning in 2010. Toxicity was graded according to the Common Terminology Criteria for Adverse
Events, version 4.0. Acute toxicity was defined as symptoms ≤6 months after VBT and chronic toxicity as >6 months after VBT. If prospective toxicity data were unavailable for a given patient (ie, if a patient was lost to follow up in the radiation oncology clinic but continued to follow up with their gynecologic oncologist, or for patients seen in our department before 2010), toxicity data were retrospectively collected from information available in the follow-up notes.

The following clinical outcomes were analyzed: LR, regional recurrence (RR), distant metastasis (DM), disease-free survival (DFS), cause-specific survival (CSS), and overall survival (OS). For the purpose of this study, LR was defined as vaginal recurrence and RR as nonvaginal pelvic recurrence. Any occurrences of LR, RR, or DM were recorded, even if not the first recurrence. For DFS, events were defined as the first incidence of recurrence (either LR, RR, or DM) or death due to any cause. Patients still alive were censored as of the date of last follow up. Clinical outcomes were analyzed using Kaplan–Meier estimates.

VBT is offered with the intent to improve local control; thus, we performed a univariable analysis (UVA) to identify the prognostic impact of baseline patient characteristics on LR. The following covariates were included in our analysis: age at the time of diagnosis, tumor grade, presence of LVSI, depth of invasion (<50% or ≥50% invasion), pathologic T stage, overall pathologic stage, time to brachytherapy (≤60 or >60 days), surgical lymph node evaluation, and the use of adjuvant chemotherapy. Cox proportional hazard modeling was used for the UVA. P-values < .05 were considered significant.

Results

Patient and disease characteristics

We identified 247 patients with early stage disease who received 30 Gy in 6 fractions to a depth of 5 mm between 1992 and 2018. The median follow-up time was 5.8 years (range, 0.2-24.7 years). Patient and tumor characteristics are listed in Table 1. The majority of patients (80%) in this study received HDR VBT as a monotherapy; however, 50 patients (20%) also received adjuvant chemotherapy, consisting primarily of 6 cycles of carboplatin and paclitaxel (Table 1). Forty-eight of 50 patients who received chemotherapy had either stage II disease (10%), a high-risk histology (72%), LVSI (38%), and/or a combination of grade 3 disease and deep myometrial invasion (22%). The remaining 2 patients were a 70-year-old woman with grade 3 disease (stage IA) and a 52-year-old woman with 60% myometrial invasion (grade 1, stage IB).

A total of 79 patients with either stage II disease (26 patients, 11%) or high-risk disease (defined as high-risk histology and/or combined grade 3 disease and deep myometrial invasion; present in 53 patients, 21%) were included in this study. Of these patients, 46 were included in the above subset that received both VBT and chemotherapy. The remaining 33 patients were deemed appropriate candidates for HDR VBT as a monotherapy based on the best data and guidelines available at the time when these patients were treated. Of the remaining patients, 112 (45%) were deemed to have HIR factors per the PORTEC-2 and/or GOG-99 study criteria. Specifically, 83 patients met the criteria for the PORTEC-2 study, 74 met the criteria for the GOG-99 study, and 47 met the criteria for both studies. The remaining 56 patients (23%) did not meet the criteria for high-risk or HIR disease, although 7 patients had LVSI.

Clinical outcomes

Recurrences were as follows: 11 patients (crude rate: 4.5%) experienced LR (vaginal recurrence) with a mean time to recurrence of 1.4 years (range, 0.5-3.9 years), 9 patients experienced recurrence within the radiation treatment field, and 2 patients experienced an out-of-field recurrence at the distal vagina (both patients had an endometrioid histology, and 1 patient had LVSI but the other did not). For both patients, the proximal 4 cm of the vagina (corresponding to the upper third of the vagina) had been targeted at the time of their initial VBT treatments. Seven patients experienced isolated LR and were successfully salvaged (5 patients remain alive and free of disease, 2 patients died of other causes with no evidence of disease at the time of death), 3 patients died of progressive disease, and 1 patient remains alive with progressive disease.

On UVA of the baseline patient characteristics on LR, only depth of myometrial invasion (assessed as a categorical variable, <50% or ≥50% invasion), tumor stage, and overall FIGO stage were significant predictors of LR (hazard ratios: 0.06, 0.06, and 0.05, respectively; P = .002, .003, and .003, respectively; Suppl. Table 1). Histology, tumor grade, presence of LVSI, age at the time of diagnosis, lymph node evaluation status (whether or not pelvic lymph nodes were evaluated surgically), time from surgery to VBT (≤60 or >60 days), and use of adjuvant chemotherapy were not significant predictors of LR. We examined the depth of myometrial invasion, tumor stage, and overall FIGO stage of all 11 patients who experienced LR, and all 11 patients had deep myometrial invasion (≥50%). Therefore, all 11 patients had a tumor stage (and overall FIGO stage, which was equivalent to tumor stage) of IB or greater. Nine patients were stage IB, and 2 patients were stage II. When patients were stratified by risk factors (no risk factors, HIR or high risk, or stage II disease, as defined above), the rate of LR did not significantly differ (Fig. E1; P = .24). The 5-year rate of LR was 8.4% for HIR patients, 2.4% for high-risk patients, and 4.4% for stage II patients.
The 5-year Kaplan-Meier estimates of LR and RR (nonvaginal pelvic recurrence) were 5% and 5%, respectively. The 5-year rate of distant metastases was 7%. The 5-year DFS was 83%, CSS was 96%, and OS was 91% (Table 2).

Toxicity

Acute and chronic toxicity data were available for 206 and 178 patients, respectively (Tables 3 and 4). There were no grade ≥3 acute or chronic toxicities. Grade 2

| Table 1 | Baseline characteristics of patients and tumors (N = 247) |
|---------|---------------------------------------------------------|
| Age, y median (range) | 65 (31-89) |
| Follow up, y median (range) | 5.8 (0.2-24.7) |
| Tumor size, cm median (range) | 4.0 (0.3-15) |
| Histology, n (%) | |
| Serous | 31 (13%) |
| Carcinosarcoma | 8 (3%) |
| Clear cell | 3 (1%) |
| Endometriod | 196 (80%) |
| Mixed | 9 (4%) |
| Grade, n (%) | |
| I | 93 (38%) |
| II | 80 (33%) |
| III | 60 (25%) |
| N/A | 13 (5%) |
| Unknown | 1 (1%) |
| FIGO T stage, n (%) | |
| 1a | 129 (52%) |
| 1b | 92 (37%) |
| 2 | 26 (11%) |
| FIGO stage, n (%) | |
| IA | 128 (52%) |
| IB | 92 (37%) |
| II | 26 (11%) |
| Lymphovascular space invasion, n (%) | |
| Yes | 79 (32%) |
| No | 157 (64%) |
| Unknown | 11 (4%) |
| Pelvic lymph nodes assessed surgically, n (%) | |
| Yes | 209 (85%) |
| No | 38 (15%) |
| Risk stratification, n (%) | |
| Stage II | 53 (21%) |
| High risk | 112 (45%) |
| High-intermediate risk | |
| PORTEC-2 criteria, n (%) | 75 (30%) |
| GOG-99 criteria | 48 (19%) |
| Both | 56 (23%) |
| Criteria for HR/HIR not met | |
| Yes | 50 (20%) |
| No | 119 (48%) |
| Unknown | 78 (32%) |
| Vaginal cuff treatment length, n (%) | |
| 4 cm | 215 (87%) |
| 5 cm | 12 (5%) |
| >5 cm | 10 (4%) |
| Unknown | 10 (4%) |

Abbreviations: FIGO = International Federation of Gynecology and Oncology.
Table 2: Clinical outcomes for 2- and 5-year survival and recurrence

|                          | 2 years, % | 5 years, % |
|--------------------------|------------|------------|
| Overall survival         | 97.8       | 90.9       |
| Cancer-specific survival | 98.7       | 96.2       |
| Disease-free survival    | 91.3       | 82.6       |
| Local recurrence         | 4.0        | 5.1        |
| Regional recurrence      | 3.0        | 4.6        |
| Distant metastasis       | 3.5        | 6.9        |

Table 3: Acute radiation toxicities (patients with available data, N = 206)

| General                  | None, n (%) | Grade 1, n (%) | Grade 2, n (%) |
|--------------------------|-------------|---------------|---------------|
| Fatigue                  | 184 (89)    | 22 (11)        | 0 (0)         |
| Weight loss              | 206 (100)   | 0 (0)          | 0 (0)         |
| Anorexia                 | 206 (100)   | 0 (0)          | 0 (0)         |
| Gastrointestinal         |             |               |               |
| Nausea                   | 204 (99)    | 2 (1)          | 0 (0)         |
| Vomiting                 | 205 (99.5)  | 1 (0.5)        | 0 (0)         |
| Diarrhea                 | 192 (93)    | 13 (6.5)       | 1 (0.5)       |
| Constipation             | 198 (96)    | 8 (4)          | 0 (0)         |
| Small bowel/colon obstruction | 206 (100)   | 0 (0)          | 0 (0)         |
| Rectal pain              | 206 (100)   | 0 (0)          | 0 (0)         |
| Genitourinary            |             |               |               |
| Urinary tract pain/dysuria | 204 (99)    | 2 (1)          | 0 (0)         |
| Urinary incontinence     | 192 (93)    | 8 (4)          | 6 (3)         |
| Hematuria                | 206 (100)   | 0 (0)          | 0 (0)         |
| Frequency/urgency        | 184 (89)    | 22 (11)        | 0 (0)         |
| Pelvic pain              | 200 (97)    | 6 (3)          | 0 (0)         |
| Vaginal                  |             |               |               |
| Vaginal infection/vaginitis | 204 (99)    | 1 (0.5)        | 1 (0.5)       |
| Vaginal stenosis/stricture | 200 (97)    | 5 (2.5)        | 1 (0.5)       |
| Vaginal dryness          | 200 (97)    | 2 (1)          | 4 (2)         |
| Vaginal discharge        | 186 (90.5)  | 19 (9)         | 1 (0.5)       |
| Female genital tract fistula | 206 (100)   | 0 (0)          | 0 (0)         |

5-year LR rate of 5% compares favorably with the 5-year vaginal recurrence rate of 1.8% reported in the PORTEC-2 study, particularly because the PORTEC-2 study evaluated women with HIR disease treated with HDR VBT monotherapy, whereas 32% of patients included in our study had high-risk or stage II disease. Likewise, our finding that deep myometrial invasion predicts for LR is in line with modern staging and risk-stratification criteria.

Discussion

Our data show that the 30 Gy in 6 fractions dose-fractionation schedule for HDR VBT results in acceptable local control and minimal acute and chronic toxicity. Our 5-year LR rate of 5% compares favorably with the 5-year vaginal recurrence rate of 1.8% reported in the PORTEC-2 study, particularly because the PORTEC-2 study evaluated women with HIR disease treated with HDR VBT monotherapy, whereas 32% of patients included in our study had high-risk or stage II disease. Likewise, our finding that deep myometrial invasion predicts for LR is in line with modern staging and risk-stratification criteria.

We calculated the 5-year LR rates for HIR, high-risk, and stage II patients (8.4%, 2.4%, and 4.4%, respectively), and found no significant difference in LR rates by risk group. However, caution should be used when comparing the outcomes of these risk groups, because the majority of high-risk and stage II patients received adjuvant chemotherapy (58% of these groups compared with 20% of our entire cohort). Additionally, our 5-year LR rate of 8.4% for HIR patients is higher than the rate reported in the PORTEC-2 study; however, differences in baseline patient characteristics (eg, possibly the percentage of patients with substantial LVSI) in our analysis and the PORTEC-2 study might explain this.

As previously mentioned, the PORTEC-2 study established VBT as the treatment of choice for patients with HIR endometrial cancer owing to a lower rate of grade 1 to 2 gastrointestinal toxicity (53.8% after EBRT vs 12.6% after VBT), and additional studies confirmed this. A systematic review found that VBT is very well tolerated, with <20.6% of patients experiencing grade 1 or 2 acute vaginal toxicity and <2% grade 3 to 4
toxicity. In comparison, we report <10% rates of acute vaginal toxicity and no grade ≥3 toxicity.

In the absence of randomized data, a direct comparison of the rates of toxicity after various doses of VBT is difficult. There is limited data regarding dosimetric predictors of acute and late vaginal toxicity. One study found that doses >68 Gy EQD2 to 2cc of the vagina was associated with a 20.5% rate of grade 2 toxicity, and several studies have shown that the bladder point dose does not correlate with urinary toxicity. Multiple studies have evaluated the impact of altering fractionation and timing on toxicity. Several single institution experiences investigating the use of condensed fractionation schedules, including daily fractions, have shown acceptably low rates of acute and late toxicity. Furthermore, various risk factors known to impact rates of toxicity after VBT (eg, cylinder size, vaginal treatment length, and rates of vaginal dilator use) are difficult to control for across studies, which further limits a direct comparison of our outcomes to those of other retrospective reports of toxicity after other doses.

The recent ABS Task Group Report on fractionation choices for gynecologic HDR VBT recommends several dose fractionations, but does not recommend any one scheme over another. In fact, the report highlights the lack of evidence supporting one fractionation over another, and comments that various institutions have published acceptable outcomes with several regimens. No randomized trials comparing the regimens recommended by the ABS Task Group have been conducted, and a limited number of single-institution, retrospective studies have compared dose-fractionation regimens, either alone or in combination with EBRT, showing no significant differences in local control or toxicity. Specifically, Sorbe et al. compared 15 or 30 Gy, each derived in 6 fractions and prescribed to a depth of 5 mm, and showed that local control and overall rates of vaginal, genitourinary, and gastrointestinal toxicities did not statistically differ. However, in the 30-Gy arm, there were significantly higher rates of vaginal shortening as measured by colpometry.

The 2019 ABS Task Group publication outlines the EQD210 for several of the dose-fractionation schemes, and we have listed those in comparison with our own in Table 5. The total EQD210 at a depth of 5 mm ranges from 15.62 to 31.25 Gy for other doses, while our dose has a higher EQD210 (37.5 Gy). We also listed the EQD23 for each fractionation, and showed that ours is higher (48 Gy at a depth of 5 mm, 103.3 Gy at the surface) compared with other doses (16.5-42 Gy at a depth of 5 mm, 33.6-92.4 Gy at the surface). Despite this higher equivalent dose, we report low rates of toxicity after 30 Gy in 6 fractions prescribed to a depth of 5 mm. Further work is needed to determine whether this higher dose may result in superior local control for a subset of patients with certain risk factors. The idea of further risk stratification is in

| Table 4 Chronic radiation toxicities (patients with available data, N = 178) |
|---------------------------------|------------------|------------------|
| **General**                     | None, n (%)      | Grade 1, n (%)   | Grade 2, n (%)   |
| Fatigue                         | 162 (91)         | 15 (8)           | 1 (1)            |
| Weight loss                     | 175 (98)         | 3 (2)            | 0 (0)            |
| Anorexia                        | 177 (99)         | 1 (1)            | 0 (0)            |
| **Gastrointestinal**            |                  |                  |                  |
| Nausea                          | 177 (99)         | 1 (1)            | 0 (0)            |
| Vomiting                        | 177 (99)         | 1 (1)            | 0 (0)            |
| Diarrhea                        | 164 (92)         | 11 (6)           | 3 (2)            |
| Constipation                    | 169 (95)         | 9 (5)            | 0 (0)            |
| Small bowel/colon obstruction   | 178 (100)        | 0 (0)            | 0 (0)            |
| Rectal pain                     | 173 (97)         | 4 (2%)           | 1 (1)            |
| **Genitourinary**               |                  |                  |                  |
| Urinary tract pain/dysuria      | 172 (96)         | 5 (3)            | 1 (1)            |
| Urinary incontinence            | 149 (84)         | 24 (13)          | 5 (3)            |
| Hematuria                       | 174 (98)         | 4 (2)            | 0 (0)            |
| Frequency/urgency               | 152 (85)         | 23 (13)          | 3 (2)            |
| Pelvic pain                     | 168 (94)         | 10 (6)           | 0 (0)            |
| **Vaginal**                     |                  |                  |                  |
| Vaginal infection/vaginitis     | 174 (98)         | 4 (2)            | 0 (0)            |
| Vaginal stenosis/stricture      | 135 (75)         | 37 (21)          | 5 (3)            |
| Vaginal dryness                 | 163 (92)         | 7 (4)            | 8 (4)            |
| Vaginal discharge               | 162 (91)         | 15 (8)           | 1 (1)            |
| Female genital tract fistula    | 177 (99)         | 1 (1)            | 0 (0)            |
| **Other**                       |                  |                  |                  |
| Lymphedema                      | 170 (95)         | 8 (5)            | 0 (0)            |
| Renal disorder                  | 178 (100)        | 0 (0)            | 0 (0)            |
line with current trends in early stage endometrial cancer. For instance, the ongoing PORTEC-4a trial randomizes women with HIR endometrial cancer to VBT or molecular profile-directed therapy, with observation, VBT, or EBRT depending on molecular risk factors.24

Overall, there are minimal data regarding the comparison of various dose-fractionation schemes for adjuvant HDR VBT, and the recent ABS Task Group Report on fractionation choices notes that multiple different fractionations are equally acceptable. However, the PORTEC-2 fractionation of 7 Gy × 3 fractions prescribed to a depth of 5 mm is used most commonly.6 In our analysis, 30 Gy in 6 fractions, which has a higher equivalent dose than other more commonly used dose fractionations, was associated with comparable rates of low toxicity. Future work is needed to determine whether patients with certain risk factors will benefit from this escalated dose. At this time, under what circumstances a dose of 30 Gy in 6 fractions offers any benefit to offset the additional fractions required compared with other shorter, more commonly used dose fractionations is unclear. However, we believe that this regimen may be useful in select cases where dose escalation is desirable.

This study has several limitations. First, data were gathered retrospectively; therefore, some factors with the potential to affect toxicity outcomes may not have been uniformly applied. For instance, vaginal dilators are routinely offered to patients in our clinical practice and their use is encouraged at the time of follow up, but patient compliance was not consistently recorded. Detailed information regarding vaginal dilator use would have strengthened our paper given that consistent dilator use is associated with lower rates of vaginal stenosis. Similarly, we were unable to report rates of sexual activity at baseline and follow up because these data were not routinely recorded. In addition, a more detailed comparison of the clinical outcomes and toxicities reported in this review with prior reports in the literature is beyond the scope of this study.

Also, our median follow-up time was 5.8 years, which limits conclusions regarding longer-term toxicity, which is due in part to the fact that many patients were lost to follow up after 5 years. Furthermore, toxicity data were prospectively collected for the majority of patients included in this study, but toxicity data were retrospectively collected from information available in follow-up notes for some patients for whom prospective data were not available. This limits the strength of our toxicity data. Additionally, surgical approaches were not uniform. Laparoscopic and robotic surgical staging became standard at our institution in 2006; therefore, this analysis includes outcomes of patients who received a mix of open, laparoscopic, and robotic surgery. Laparoscopic and robotic methods have similar immediate outcomes, but further work is required to investigate how surgical approaches may influence toxicity outcomes in our patient population.25 Finally, further analysis to investigate the presence

| Cylinder dose | Total surface EQD2_{20(Gy)} | Total 5-mm depth EQD2_{3 (Gy)} |
|---------------|-----------------------------|--------------------------------|
| 7 Gy × 3      | 57.75                       | 29.75                          |
| 5 Gy × 4      | 54.23                       | 28.42                          |
| 5 Gy × 5      | 50.9                         | 25.49                          |
| 5 Gy × 5, Surface | 54.69                  | 28.92                          |
| 6 Gy × 5      | 40.15                       | 22.59                          |
| 6 Gy × 6      | 28                           | 15.62                          |

Abbreviations: EQD2 = equivalent total dose in 2-Gy fractions. * Dose-fractionation scheme used at our institution.
of LVSI as a risk factor in this population is planned, because the presence of LVSI is a known poor prognostic indicator for recurrence and survival.26

Conclusions

This study shows that the dose-fractionation schedule of 30 Gy in 6 fractions results in acceptable clinical outcomes with minimal toxicity, and is comparable to the recommended dose-fractionation schedules in the ABS guidelines. This dose fractionation has a higher equivalent dose than other more commonly used doses, but was associated with comparable rates of low toxicity. Future work is needed to better define whether certain patients may benefit from this escalated dose.

Acknowledgments

The authors thank the Beaumont Health System, Departments of Radiation Oncology and Gynecologic Oncology, for their support.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jandro.2021.100773.

References

1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019.
2. Abu-Rustum NR, Bean S, Bradley K, et al. Uterine neoplasms, version 1.2020. J Natl Comg Cancer Neto. 2020. [Epub ahead of print].
3. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A gynecologic oncology group study. Gynecol Oncol. 2004;92:744–751.
4. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–823.
5. Small Jr W, Beriwala S, Demanes DJ, et al. American brachytherapy society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012;11:58–67.
6. Albuquerque K, Hrycyszuk BA, Harkenrider MM, et al. Compendium of fractionation choices for gynecologic HDR brachytherapy. An American Brachytherapy Society Task Group report. Brachytherapy. 2019;18:429–436.
7. Harkenrider MM, Grover S, Erickson BA, et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 survey of the American Brachytherapy Society. Brachytherapy. 2016;15:23–29.
8. Delishaj D, Barcellini A, D’Amico R, et al. Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results. J Contemp Brachytherapy. 2018;10:559–566.
9. Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol. 2005;97:887–892.
10. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: A randomized study of two dose-per-fraction levels. Int J Radiat Oncol Biol Phys. 2005;62:1385–1389.
11. Aguilera MDV, Rovirosa A, Ascaso C, et al. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction (alpha/beta=3 Gy) at 2 cm2 of vagina. J Contemp Brachytherapy. 2018;10:40–46.
12. Donnelly ED, Rahra S, Helenowski I, et al. Dosimetry and toxicity outcomes in postoperative high-dose-rate intracavitary brachytherapy for endometrial carcinoma. J Contemp Brachytherapy. 2012;4:135–140.
13. Sapienza LG, Aiza A, Gomes MJ, et al. Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer. J Contemp Brachytherapy. 2015;7:357–362.
14. Valdivuezio I, Rovirosa A, Herreros A, et al. Three or four fractions per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. The long-term results on vaginal relapses and toxicity. Clin Transl Oncol. 2013;15:602–607.
15. Rios I, Rovirosa A, Ascaco C, et al. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients. Clin Transl Oncol. 2016;18:925–930.
16. Bahng AY, Dagan A, Bruner DW, et al. Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. Int J Radiol Oncol Biol Phys. 2012;82:667–673.
17. Fiorentino A, Chiumento C, Fuscio V. Do comorbidity influences acute toxicity and outcome in elderly patients with endometrial cancer treated by adjuvant radiotherapy plus brachytherapy? Clin Transl Oncol. 2013;15:665–669.
18. Park HS, Ratner ES, Lucarelli L, et al. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy. 2015;14:464–470.
19. Qian JM, Stahl JM, Young MR, et al. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. J Gynecol Oncol. 2017;28:e84.
20. Smits A, McGrane J, Lopes A, et al. Radiation-related toxicities and outcomes in endometrial cancer: Are obese women at a disadvantage? Int J Clin Oncol. 2017;22:945–953.
21. Papathemelis T, Schar L, Hipp M, et al. Quality of life and oncological outcome in endometrial cancer patients after vaginal brachytherapy: Comparison of two dosing schemes. Arch Gynecol Obstet. 2019;299:507–514.
22. Rovirosa A, Ascaco C, Arenas M, et al. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules. Radiother Oncol. 2015;116:143–148.
23. Rovirosa A, Herreros A, Camacho C, et al. Comparative results of three short brachytherapy schedules as exclusive treatment in postoperative endometrial carcinoma. Brachytherapy. 2017;16:1169–1174.
24. Wortman BG, Bosse T, Nout RA, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. Gynecol Obstet. 2018;151:69–75.
25. Madhuri TK, Butler-Manuel S. Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: A randomized controlled trial. Am J Obstet Gynecol. 2017;216:619.
26. Weinberg LE, Kunos CA, Zanotti KM. Lymphovascular space invasion (LVSI) is an isolated poor prognostic factor for recurrence and survival among women with intermediate- to high-risk early-stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2013;23:1438–1445.